Document:

Registration Rights Agreement

 Exhibit 10.2 
 REGISTRATION RIGHTS AGREEMENT 
 This REGISTRATION
RIGHTS AGREEMENT (this “Agreement”) is made as of the 31st day of May 2012, between DayStar Technologies, Inc., a Delaware corporation (the “Company”), and the individuals listed on Schedule I (the
“Recipients”). The Company and the Recipients are sometimes referred to individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 A. Pursuant to that certain Securities Purchase Agreement dated May 31, 2012 (the “Purchase Agreement”) the Company has agreed to issue to the Recipients an aggregate of
285,714 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”). 
 B. In connection with the issuance of the Shares to the Recipients, the Company desires to grant to the Recipients and their respective successors and permitted assigns certain registration rights with
respect to Shares. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter set forth, the Parties agree as follows. 

ARTICLE I. 

REGISTRATION RIGHTS 
 Section 1.1 Definitions. For purposes of this Agreement: 

“Affiliate” means, with respect to any Person, (i) any other Person of which securities or other ownership
interests representing more than 50% of the voting interests are, at the time such determination is being made, owned, Controlled or held, directly or indirectly, by such Person or (ii) any other Person which, at the time such determination is
being made, is Controlling, Controlled by or under common Control with, such Person. “Control,” whether used as a noun or verb, refers to the possession, directly or indirectly, of the power to direct, or cause the direction
of, the management or policies of a Person, whether through the ownership of voting securities or otherwise. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Holder” means a Person that (i) is a party to this Agreement (or a permitted transferee under
Section 2.2) and (ii) owns Registrable Securities; provided, however, that for purposes of this Agreement, Holders of Registrable Securities will not be required to convert the Note or exercise the Warrant into Common
Stock to exercise the registration rights granted hereunder, until immediately before the closing of the offering to which the registration relates. 

 “Participating Holders” means Holders participating, or electing to
participate, in an offering of Registrable Securities. 
 “Person” means any individual, firm,
corporation, company, partnership, trust, incorporated or unincorporated association, limited liability company, joint venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and will
include any successor (by merger or otherwise) of any such entity. 
 “Registrable Securities” means the
Shares and any other shares of the Company’s Common Stock issued or issuable with respect to the Shares by virtue of any stock split, combination, stock dividend, merger, consolidation or other similar event; provided, however,
that shares of Common Stock that are considered to be Registrable Securities will cease to be Registrable Securities (A) upon the sale thereof pursuant to an effective registration statement, (B) upon the sale thereof pursuant to Rule 144
(or successor rule) under the Securities Act where the Recipients thereof receives unrestricted securities, (C) when such securities cease to be outstanding or (D) in a private transaction where the transferor’s rights under this
Agreement are not assigned. 
 “Registration Expenses” mean all expenses (other than underwriting
discounts and commissions) arising from or incident to the performance of or compliance with this Agreement, including without limitation (i) SEC, stock exchange, the Financial Industry Regulatory Authority (“FINRA”) and
other registration and filing fees, (ii) all fees and expenses incurred in connection with complying with any securities or blue sky laws, (iii) all printing, messenger and delivery expenses, (iv) the fees, charges and disbursements
of counsel to the Company and of its independent public accountants and any other accounting and legal fees, charges and expenses incurred by the Company (including, without limitation, any expenses arising from any special audits or “comfort
letters” required in connection with or incident to any registration), (v) the fees, charges and disbursements of any special experts retained by the Company in connection with any registration pursuant to the terms of this Agreement,
(vi) all internal expenses of the Company, and (vii) the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange, in each case regardless of whether any Registration Statement is
declared effective. 
 “Registration Statement” will mean any registration statement of the Company
filed with the SEC on the appropriate form pursuant to the Securities Act which covers any of the shares of Common Stock and any other Registrable Securities pursuant to the provisions of this Agreement and all amendments and supplements to any such
Registration Statement, including post-effective amendments, in each case including the prospectus contained therein, all exhibits thereto and all materials incorporated by reference therein. 

“SEC” means the United States Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Selling Expenses” will mean the underwriting fees, discounts, selling commissions and stock transfer taxes
applicable to all Registrable Securities registered by the Participating Holders. 

  
 2 

 Section 1.2 Filing of Registration Statement. Obligation to File
Registration Statement. The Company agrees to file a Registration Statement under the Securities Act covering the sale or other distribution of all or any portion of the Registrable Securities pursuant to Rule 415 under the Securities Act. The
Company will use its commercially reasonable efforts to have such Registration Statement declared effective by the SEC as soon as practicable thereafter (the “Effectiveness Deadline”). 

Section 1.3 Registration Procedures. 

(a) Obligations of the Company. Whenever registration of Registrable Securities is required pursuant to this
Agreement, the Company will use its reasonable efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method of distribution thereof as promptly as possible, and in connection with any such
request, the Company will, as expeditiously as possible: 
 (i) Preparation of Registration Statement;
Effectiveness. Prepare and file with the SEC a Registration Statement on any form on which the Company then qualifies, which counsel for the Company will deem appropriate and pursuant to which such offering may be made in accordance with the
intended method of distribution thereof (except that the Registration Statement will contain such information as may reasonably be requested for marketing or other purposes by the managing underwriter), and use reasonable best efforts to cause any
registration required hereunder to become effective as soon as practicable after the initial filing thereof (unless a specific time period is otherwise set forth herein) and remain effective for a period of not less than one year from the effective
date thereof or such shorter period in which all Registrable Securities have been sold in accordance with the methods of distribution set forth in the Registration Statement; provided that, in the case of any registration of Registrable
Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such one-year period will be extended, if necessary, to keep the Registration Statement effective until all such Registrable Securities are sold,
provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis; 
 (ii) Participation in Preparation. Provide any Participating Holder, any underwriter participating in any disposition pursuant to a Registration Statement, and any attorney, accountant or other
agent retained by any Participating Holder or underwriter (collectively, the “Inspectors”), the opportunity to participate in the preparation of such Registration Statement, each prospectus included therein or
filed with the SEC and each amendment or supplement thereto; 
 (iii) Due Diligence. For a reasonable
period prior to the filing of any Registration Statement pursuant to this Agreement, make 

  
 3 

 
available for inspection and copying by the Inspectors such financial and other information and books and records, pertinent corporate documents and properties of the Company and its subsidiaries
and cause the officers, directors, employees, counsel and independent certified public accountants of the Company and its subsidiaries to respond to such inquiries and to supply all information reasonably requested by any such Inspector in
connection with such Registration Statement, as will be reasonably necessary, in the judgment of the respective counsel, to conduct a reasonable investigation within the meaning of the Securities Act; provided, however, that if
requested by the Company, each Inspector will enter into a confidentiality agreement with the Company prior to the Company’s release or disclosure of confidential information to such Inspector; 

(iv) General Notifications. Promptly notify in writing the Participating Holders, the sales or placement agent, if
any, therefor and the managing underwriter of the securities being sold, (A) when such Registration Statement or the prospectus included therein or any prospectus amendment or supplement or post-effective amendment has been filed, and, with
respect to any such Registration Statement or any post-effective amendment, when the same has become effective, (B) when the SEC notifies the Company whether there will be a “review” of such Registration Statement and (C) of any
comments (oral or written) by the SEC and by the blue sky or securities commissioner or regulator of any state with respect thereto or (D) of any request by the SEC for any amendments or supplements to such Registration Statement or the
prospectus or for additional information; 
 (v) 10b-5 Notification. Promptly notify in writing the
Participating Holders, the sales or placement agent, if any, therefor and the managing underwriter of the securities being sold pursuant to any Registration Statement at any time when a prospectus relating thereto is required to be delivered under
the Securities Act upon discovery that, or upon the happening of any event as a result of which, any prospectus included in such Registration Statement (or amendment or supplement thereto) contains an untrue statement of a material fact or omits to
state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, and the Company will promptly prepare a supplement or amendment to such
prospectus and file it with the SEC (in any event no later than ten days following notice of the occurrence of such event to each Participating Holder, the sales or placement agent and the managing underwriter) so that after delivery of such
prospectus, as so amended or supplemented, to the Recipients of such Registrable Securities, such prospectus, as so amended or supplemented, will not contain an untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made; 

  
 4 

 (vi) Notification of Stop Orders; Suspensions of Qualifications and
Exemptions. Promptly notify in writing the Participating Holders, the sales or placement agent, if any, therefor and the managing underwriter of the securities being sold of the issuance by the SEC of (A) any stop order issued or threatened
to be issued by the SEC or (B) any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of any
proceeding for such purpose and the Company will use reasonable efforts to (x) prevent the issuance of any such stop order, and in the event of such issuance, to obtain the withdrawal of any such stop order and (y) obtain the withdrawal of
any order suspending or preventing the use of any related prospectus or suspending the qualification of any Registrable Securities included in such Registration Statement for sale in any jurisdiction at the earliest practicable date; 

(vii) Amendments and Supplements; Acceleration. Prepare and file with the SEC such amendments, including
post-effective amendments, as may be necessary to keep each Registration Statement continuously effective for the applicable time period required hereunder and if applicable, file any Registration Statements pursuant to Rule 462(b) under the
Securities Act; cause the related prospectus to be supplemented by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 (or any similar provisions then in force) promulgated under the Securities Act; and comply
with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all securities covered by such Registration Statement during such period in accordance with the intended methods of disposition by the sellers thereof
set forth in such Registration Statement as so amended or in such prospectus as so supplemented; 
 (viii)
Copies. Furnish as promptly as practicable to each Participating Holder copies of such Registration Statement, supplement or amendment as it is proposed to be filed, and after such filing such number of copies of such Registration Statement,
each amendment and supplement thereto (in each case including all exhibits thereto), the prospectus included in such Registration Statement (including each preliminary prospectus) and such other documents as each such Participating Holder or
underwriter may reasonably request; 
 (ix) Blue Sky. Use reasonable efforts to, prior to any public
offering of the Registrable Securities, register or qualify (or seek an exemption from registration or qualifications) such Registrable Securities under such other securities or blue sky laws of such jurisdictions as any

  
 5 

 
Participating Holder or underwriter may request, and to continue such qualification in effect in each such jurisdiction for as long as is permissible pursuant to the laws of such jurisdiction, or
for as long as a Participating Holder or underwriter requests or until all of such Registrable Securities are sold, whichever is shortest, and do any and all other acts and things which may be reasonably necessary or advisable to enable any
Participating Holder to consummate the disposition in such jurisdictions of the Registrable Securities; 
 (x)
Other Approvals. Use reasonable efforts to obtain all other approvals, consents, exemptions or authorizations from such governmental agencies or authorities as may be necessary to enable the Participating Holders and underwriters to
consummate the disposition of Registrable Securities; 
 (xi) “Cold Comfort” Letter.
Obtain a “cold comfort” letter from the Company’s independent public accountants in customary form and covering such matters of the type customarily covered by “cold comfort” letters as the managing underwriter may
reasonably request, and reasonably satisfactory to a majority in interest of the Participating Holders; 
 (xii)
Legal Opinion. Furnish, at the request of any underwriter of Registrable Securities on the date such securities are delivered to the underwriters for sale pursuant to such registration, an opinion, dated such date, of counsel representing the
Company for the purposes of such registration, addressed to the Holders, and the placement agent or sales agent, if any, thereof and the underwriters, if any, thereof, covering such legal matters with respect to the registration in respect of which
such opinion is being given as such underwriter may reasonably request and as are customarily included in such opinions; 
 (xiii) Certificates, Closing. Provide officers’ certificates and other customary closing documents; 
 (xiv) FINRA. Cooperate with each Participating Holder and each underwriter participating in the disposition of such Registrable Securities and underwriters’ counsel in connection with any
filings required to be made with the FINRA; 
 (xv) Listing. Use reasonable efforts to cause all such
Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are then listed and if not so listed, to be listed on the over-the-counter system; 

(xvi) Private Sales. Use reasonable efforts to assist a Holder in facilitating private sales of Registrable
Securities by, among other things, providing officers’ certificates and other customary closing documents reasonably requested by a Holder; and 

  
 6 

 (xvii) Reasonable Efforts. Use reasonable efforts to take all other
actions necessary to effect the registration of the Registrable Securities contemplated hereby. 
 (b) Seller
Information. The Company may require each Participating Holder as to which any registration of such Holder’s Registrable Securities is being effected to furnish to the Company with such information regarding such Participating Holder and
such Participating Holder’s method of distribution of such Registrable Securities as the Company may from time to time reasonably request in writing. 
 (c) Notice to Discontinue. Each Participating Holder whose Registrable Securities are covered by a Registration Statement filed pursuant to this Agreement will, upon receipt of written notice from
the Company of the happening of any event of the kind described in Section 1.3(a)(v), forthwith discontinue the disposition of Registrable Securities until such Participating Holder’s receipt of the copies of the supplemented or
amended prospectus contemplated by Section 1.3(a)(v) or until it is advised in writing by the Company that the use of the prospectus may be resumed and has received copies of any additional or supplemental filings which are incorporated
by reference into the prospectus. If the Company will give any such notice, the Company will extend the period during which such Registration Statement is to be maintained effective by the number of days during the period from and including the date
of the giving of such notice pursuant to Section 1.3(a)(v) to and including the date when the Participating Holder will have received the copies of the supplemented or amended prospectus contemplated by, and meeting the requirements of,
Section 1.3(a)(v). 
 Section 1.4 Registration Expenses. Except as otherwise provided herein, all
Registration Expenses will be borne by the Company. All Selling Expenses relating to Registrable Securities registered will be borne by the Participating Holders of such Registrable Securities pro rata on the basis of the number of shares so
registered. 
 Section 1.5 Indemnification 

(a) Indemnification by the Company. Notwithstanding termination of this Agreement, the Company will indemnify and
hold harmless to the fullest extent permitted by law, each Holder, each of its directors, officers, employees, advisors, agents and general or limited partners (and the directors, officers, employees, advisors and agents thereof), their respective
Affiliates and each Person who controls (within the meaning of the Securities Act or the Exchange Act) any of such Persons, and each underwriter and each Person who controls (within the meaning of the Securities Act or the Exchange Act) any
underwriter (collectively, “Holder Indemnified Parties”) from and against any and all losses, 

  
 7 

 
claims, damages, expenses (including, without limitation, reasonable costs of investigation and fees, disbursements and other charges of counsel, any amounts paid in settlement effected with the
Company’s consent, which consent will not be unreasonably withheld or delayed and any costs incurred in enforcing the Company’s indemnification obligations hereunder) or other liabilities (collectively,
“Losses”) to which any such Holder Indemnified Party may become subject under the Securities Act, Exchange Act, any other federal law, any state or common law or any rule or regulation promulgated thereunder or
otherwise, insofar as such Losses (or actions or proceedings, whether commenced or threatened, in respect thereof) are resulting from or arising out of or based upon (i) any untrue, or alleged untrue, statement of a material fact contained in
any Registration Statement, prospectus or preliminary prospectus (as amended or supplemented) or any document incorporated by reference in any of the foregoing or resulting from or arising out of or based upon any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, in light of the circumstances under which they were made), not misleading or (ii) any violation by the Company
of the Securities Act, Exchange Act, any other federal law, any state or common law or any rule or regulation promulgated thereunder or otherwise incident to any registration, qualification or compliance, and in any such case, the Company will
promptly reimburse each such Holder Indemnified Party for any legal and any other Losses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability, action or investigation or proceeding
(collectively, a “Claim”); provided, however, that the liability of the Company under this Section 1.5(a) will be limited to an amount equal to the sum of the principal amount of the Note plus all
accrued unpaid interest earned thereon at the time the Claim was made and the exercise price of the Warrant and that the Company will not be liable to any Holder Indemnified Party for any Losses that arise out of or are based upon (x) written
information provided by a Holder Indemnified Party expressly for use in the Registration Statement or (y) sales of Registrable Securities by a Holder Indemnified Party to a person to whom there was not sent or given, at or before the written
confirmation of such sale, a copy of the prospectus (excluding documents incorporated by reference) or the prospectus as then amended or supplemented (excluding documents incorporated by reference) if the Company has previously furnished in a timely
manner a reasonable number of copies thereof to such Holder Indemnified Party in compliance with this Agreement and the Losses of such Holder Indemnified Party results from an untrue statement or omission of a material fact contained in such
preliminary prospectus which was corrected in the prospectus (or the prospectus as then amended or supplemented). Such indemnity will remain in full force and effect regardless of any investigation made by or on behalf of the Holder Indemnified
Parties and will survive the transfer of Registrable Securities by such Holder Indemnified Parties. 
 (b)
Indemnification by Holders. In connection with any proposed registration in which a Holder is participating pursuant to this Agreement, each such Holder will furnish to the Company in writing such information with respect

  
 8 

 
to such Holder as the Company may reasonably request or as may be required by law for use in connection with any Registration Statement or prospectus or preliminary prospectus to be used in
connection with such registration and each Holder, severally and not jointly, will indemnify and hold harmless the Company, any underwriter retained by the Company and their respective directors, officers, partners, employees, advisors and agents,
their respective Affiliates and each Person who controls (within the meaning of the Securities Act or the Exchange Act) any of such Persons to the same extent as the foregoing indemnity from the Company to the Holders as set forth in
Section 1.5(a) (subject to the exceptions set forth in the foregoing indemnity, the proviso to this sentence and applicable law), but only with respect to any such information furnished in writing by such Holder expressly for use therein
and not with respect to any other Holder or the Company; provided, however, that the liability of any Holder under this Section 1.5(b) will be limited to the amount of the net proceeds received by such Holder in the
offering giving rise to such liability. Such indemnity obligation will remain in full force and effect regardless of any investigation made by or on behalf of the Holder Indemnified Parties (except as provided above) and will survive the transfer of
Registrable Securities by such Holder. 
 (c) Conduct of Indemnification Proceedings. Any Person entitled
to indemnification hereunder (the “Indemnified Party”) will give prompt written notice to the indemnifying party (the “Indemnifying Party”) after the receipt by the
Indemnified Party of any written notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified Party intends to claim indemnification or contribution pursuant to this
Agreement; provided, however, that, the failure so to notify the Indemnifying Party will not relieve the Indemnifying Party of any liability that it may have to the Indemnified Party hereunder unless and to the extent such Indemnifying
Party is materially prejudiced by such failure. If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party will be entitled to participate in and, to the extent it may wish, jointly with
any other Indemnifying Party similarly notified, to assume the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified Party will have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel will be paid by the Indemnified Party unless the Indemnifying Party fails to assume the defense of such action with counsel The Indemnifying
Party will not have the right to assume the defense of such action on behalf of such Indemnified Party. No Indemnifying Party will be liable for any settlement entered into without its written consent, which consent will not be unreasonably
withheld. No Indemnifying Party will, without the written consent of the Indemnified Party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of
which indemnification or contribution may be sought hereunder (whether or not the Indemnified Party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (A) includes an unconditional release of
the Indemnified Party from all liability 

  
 9 

 
arising out of such action or claim and (B) does not include a statement as to, or an admission of, fault, culpability or a failure to act by or on behalf of any Indemnified Party. The
rights afforded to any Indemnified Party hereunder will be in addition to any rights that such Indemnified Party may have at common law, by separate agreement or otherwise. 

(d) Contribution. If the indemnification provided for in this Section 1.5 from the Indemnifying Party
is unavailable or insufficient to hold harmless an Indemnified Party in respect of any Losses referred to herein, then the Indemnifying Party, in lieu of indemnifying the Indemnified Party, will contribute to the amount paid or payable by the
Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and the Indemnified Party, as well as any other relevant equitable considerations. The relative faults of the
Indemnifying Party and Indemnified Party will be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material
fact, was made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the Indemnifying Party’s and Indemnified Party’s relative intent, knowledge, access to information and opportunity to correct or
prevent such action; provided, however, that the liability of any Holder under this Section 1.5(d) will be limited to the amount of the net proceeds received by such Holder in the offering giving rise to such liability and
the liability of the Company will be limited to an amount as stated in Section 1.5(a). The amount paid or payable by a party as a result of the Losses or other liabilities referred to above will be deemed to include, subject to the
limitations set forth in Sections 1.5(a), 1.5(b) and 1.5(c), any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The Parties agree that it would not
be just and equitable if contribution pursuant to this Section 1.5(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the foregoing.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution pursuant to this Section 1.5(d). 

Section 1.6 Rule 144 and Rule 144A; Other Exemptions. With a view to making available to the Holders the benefits of
Rule 144 and Rule 144A promulgated under the Securities Act and other rules and regulations of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration, the Company covenants that it will
(a) file in a timely manner all reports and other documents required to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted by the SEC thereunder and (b) take such further action as each
Holder may reasonably request (including, but not limited to, providing any information necessary to comply with Rule 144 and Rule 144A, if available with respect to resales of the Registrable Securities under the Securities Act), at all times from
and after the date hereof all to the extent required from time to time to enable such Holder to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 and Rule
144A (if available with respect to 

  
 10 

 
resales of the Registrable Securities) under the Securities Act, as such rules may be amended from time to time or (ii) any other rules or regulations now existing or hereafter adopted by
the SEC. 
 Section 1.7 Certain Limitations On Registration Rights. No Holder may participate in any
Registration Statement hereunder unless such Holder completes and executes all questionnaires and other documents reasonably required and will sell such Holder’s Registrable Securities on the basis provided in any underwriting agreement
approved by the Holder or Holders entitled hereunder to approve such arrangements. Such Holders of Registrable Securities to be sold by such underwriters may, at their option, require that any or all of the representations and warranties by, and the
other agreements on the part of the Company to and for the benefit of such underwriters, will also be made to and for the benefit of such Holders and that any or all of the conditions precedent to the obligations of the underwriters under the
underwriting agreement be conditions precedent to the obligations of the Holders. 
 ARTICLE II. 

GENERAL PROVISIONS 
 Section 2.1 Entire Agreement. This Agreement, together with the Schedules hereto and any certificates, documents, instruments and writings that are delivered
pursuant hereto, constitutes the entire agreement and understanding of the Parties in respect of the registration of the Registrable Securities and supersedes all prior understandings, agreements or representations by or among the Parties, written
or oral, to the extent they relate in any way to the subject matter hereof. Nothing in this Agreement shall be deemed to alter the restrictions on resale set forth in Section 5 of the Purchase Agreement.  

Section 2.2 Assignment; Binding Effect. No Party may assign either this Agreement or any of its rights,
interests or obligations hereunder without the prior written approval of the other Party; provided that the rights of a Holder may be transferred or assigned in connection with a transfer of Registrable Securities to the extent that all of the
following additional conditions are satisfied: (a) such transfer or assignment is effected in accordance with applicable securities laws; (b) such transferee or assignee agrees in writing to become subject to the terms of this Agreement;
and (c) the Company is given written notice by such Holder of such transfer or assignment, stating the name and address of the transferee or assignee and identifying the Registrable Securities with respect to which such rights are being
transferred or assigned. All of the terms, agreements, covenants, representations, warranties and conditions of this Agreement are binding upon, and inure to the benefit of and are enforceable by, the Parties and their respective successors and
permitted assigns. 
 Section 2.3 Notices. All notices or other communications to a Party required or
permitted hereunder will be in writing and will be delivered personally or by facsimile (receipt confirmed electronically) to such Party (or, in the case of an entity, to an executive officer of such party) or will be sent by a reputable express
delivery service or by certified mail, postage prepaid with return receipt requested, addressed as follows: 
 If to the
Recipients, to the address set forth on Schedule I. 

  
 11 

 If to the Company: 

DayStar Technologies, Inc. 
 33556 Alvarado Niles Road 
 Union City, CA 94587 

Attn: Mr. Christopher Lail 
          Chief Financial Officer 
 Any party may
change the above specified recipient and/or mailing address by notice to all other parties given in the manner herein prescribed. All notices will be deemed given on the day when actually delivered as provided above (if delivered personally or by
facsimile, provided that any such facsimile is received during regular business hours at the recipient’s location) or on the day shown on the return receipt (if delivered by mail or delivery service). 

Section 2.4 Specific Performance; Remedies. Each Party agrees that the other Party would be damaged irreparably if any
provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached. Accordingly, the Parties will be entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement and to
enforce specifically this Agreement and its provisions in any action or proceeding instituted any court of the United States or any state thereof having jurisdiction over the Parties and the matter, in addition to any other remedy to which they may
be entitled, at law or in equity. Except as expressly provided herein, the rights, obligations and remedies created by this Agreement are cumulative and in addition to any other rights, obligations or remedies otherwise available at law or in
equity. Except as expressly provided herein, nothing herein will be considered an election of remedies. 
 Section 2.5
Governing Law; Waiver of Jury Trial. This Agreement will be governed by and construed under the laws of the State of New York, without giving effect to conflicts of laws principles that would require the application of the laws of any
other jurisdiction. THE PARTIES EACH HEREBY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, WAIVE THEIR RESPECTIVE RIGHTS TO JURY TRIAL OF ANY DISPUTE BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OTHER AGREEMENTS RELATING HERETO OR ANY
DEALINGS AMONG THEM RELATING TO THE TRANSACTIONS. 
 Section 2.6 Headings. The titles and headings to the
Sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement will be construed without regard to any presumption or other rule
requiring construction hereof against the party causing this Agreement to be drafted. 
 Section 2.7
Amendments. This Agreement may not be amended or modified without the written consent of the Company and at least a majority in interest of the Holders. 
 Section 2.8 Extensions; Waivers. No waiver by any Party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, may be deemed to
extend to any prior or subsequent default, misrepresentation or breach of warranty 

  
 12 

 
or covenant hereunder or affect in any way any rights arising because of any prior or subsequent such occurrence. Neither the failure nor any delay on the part of any party to exercise any right
or remedy under this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any right or remedy preclude any other or further exercise of the same or of any other right or remedy. 

Section 2.9 Severability. The provisions of this Agreement will be deemed severable and the invalidity or
unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party or to any circumstance, is judicially determined not to be
enforceable in accordance with its terms, the Parties agree that the court judicially making such determination may modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or
phrases, and in its modified form, such provision will then be enforceable and will be enforced. 
 Section 2.10
Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

Section 2.11 Adjustments for Stock Splits, Etc. Wherever in this Agreement there is a reference to a specific number
of shares of the Company’s capital stock of any class or series, then, upon the occurrence of any subdivision, combination or stock dividend of such class or series of stock, the specific number of shares so referenced in this Agreement will
automatically be proportionally adjusted to reflect the effect of such subdivision, combination or stock dividend on the outstanding shares of such class or series of stock. 
 [SIGNATURE PAGE FOLLOWS] 

  
 13 

 IN WITNESS WHEREOF, the Parties have executed this Registration Rights Agreement as of the
date first above written. 
  

							
	COMPANY:	 		 	DAYSTAR TECHNOLOGIES, INC.
				
		 		 	By:	 	 /s/ Peter Lacey

		 		 	Name: Peter Lacey
		 		 	Title: Interim President and CEO
			
	RECIPIENTS:	 		 	Ronald Garry Yost
			
		 		 	 /s/ Ronald Garry Yost

  

 SCHEDULE I 
 RECIPIENTS: 
 Ronald Garry YostOffer Letter

 Exhibit 10.1 
 May 29, 2012 
 John A. Kollins 
 Dear John: 
 I am pleased to offer you a position with Transcept Pharmaceuticals
(the “Company”) as Senior Vice President, Chief Business Officer. The position will be based out of our offices located at 1003 W. Cutting Blvd., Suite 110, Pt. Richmond, California. If you decide to join us you will receive a monthly
salary of $28,333.33 less required deductions and withholdings, which will be paid semi-monthly in accordance with the Company’s normal payroll procedures. 
 You will also be eligible to participate in the executive bonus program with a target bonus of up to 35% of your base salary. At Transcept our salary merit increases and potential bonus amounts, if any,
are based upon the assumption that an employee has provided services to the Company for the entire calendar year. Due to your prior half-time consulting history with the Company, if you join Transcept on June 1, 2012, your potential bonus, if
awarded, will be pro-rated such that you are eligible to receive up to 75% of your 35% target bonus. If you leave at any time during a year, you will not be eligible for any pro-rata amount of your unearned target bonus for that year. Bonus payments
will be subject to required deductions and withholdings. The Company shall have the sole discretion to determine whether you have earned any bonus set forth in this paragraph and, if so, the amount of any such bonus. 

As an employee, you are also eligible to receive certain employee benefits that currently include health, dental, life and vision
insurance as well as a 401(k) plan pursuant to the terms of these benefit plans. You should note that the Company may modify compensation and benefits from time to time as it deems necessary. 

In addition, if you decide to join us, it will be recommended to the Company’s Compensation Committee at the first meeting of the
Compensation Committee following your start date, that the Company grant you an option to purchase 85,000 shares of the Company’s Common Stock at a price per share equal to the fair market value per share of the Common Stock on the date of
grant, as determined by the closing price. If granted, 25% of the shares subject to the option shall vest 12 months after the date your vesting begins (and, except as provided in your Change of Control and Severance Benefit Agreement), no shares
shall vest before such date and no rights to any vesting shall be earned or accrued prior to such date) and the remaining shares subject to the option shall vest monthly over the next 36 months in equal monthly amounts subject to your continuing
employment with the Company. This option grant shall be subject to the terms and conditions of the Company’s Stock Option Plan and Stock Option Agreement. Over time, additional performance-based stock option grants may be made available in the
sole discretion of the Company. 

 The Company also will enter into a Change of Control and Severance Benefits Agreement (the
“Severance Agreement”) with you. 
 Any successor in interest to the Company shall be bound by the terms of this
Agreement. 
 The Company is excited about the prospect of having you join our team, and we look forward to a beneficial and
fruitful relationship. Nevertheless, you should be aware that your employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason.
Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without advance notice. We request that, in the event of resignation, you give the Company at least two-week’s
notice. 
 Due to requirements under its DEA application the company conducts background checks on all of its potential
employees. Your job offer, therefore, in contingent upon a clearance of such a background investigation. 
 For purposes of
federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your
date of hire, or our employment relationship with you may be terminated. 
 We also ask that, if you have not already done so,
you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any
such agreements will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your
obligations to the Company, subject to the below. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer(s), and that in performing your duties for the Company, you will not
in any way utilize any such information. 
 As you know, Transcept is involved in an industry that is highly competitive
and that changes quickly. Thus, although the position we are offering is as its Senior Vice President, Chief Business Officer, Transcept may change your position and/or your duties at any time, with or without cause or advance notice. As with all of
our employees, your employment is also subject to our general employment policies, many of which are described in our Employee Handbook. As a Company employee, you will be expected to abide by company rules and standards. You will be specifically
required to sign an acknowledgment that you have read and that you understand the Company’s rules of conduct, which are included in the Company Handbook. 
 As a condition of your employment, you will also be required to sign and comply with an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement which requires,
among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of proprietary information. In the event of any dispute or claim relating to or arising out of this agreement or
our employment relationship, you and the Company agree to an arbitration in which (i) you are 

 
waiving any and all rights to a jury trial but all court remedies will be available in arbitration, (ii) we agree that all disputes between you and the Company shall be fully and finally
resolved by binding arbitration, (iii) all disputes shall be resolved by a single neutral arbitrator who shall issue a written opinion, (iv) the arbitration proceeding shall provide for adequate discovery, and (v) the Company shall
pay all arbitration fees in excess of any court fees which you would be required to pay if the dispute were decided in a court of law. Any such arbitration shall be conducted in the San Francisco Bay Area by Judicial Arbitration and Mediation
Services (JAMS) under the JAMS Employment Arbitration Rules and Procedures. 
 To indicate your acceptance of the Company’s
offer, please sign and date this letter in the space provided below. A duplicate original is enclosed for your records. If you accept our offer, your first day of employment shall be subject to mutual agreement, but in no event be later than
June 1, 2012. This letter, along with your At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement and the Severance Agreement, sets forth the entire terms of your employment with the Company and supersede
any prior representations or agreements including, but not limited to any representations made during your interviews or relocation negotiations, whether written or oral. This letter, including, but not limited to, its at-will employment provision,
may not be modified or amended except by a written agreement signed by the Company President and you. This offer of employment will terminate if it is not accepted, signed and returned by May 25, 2012. 

We look forward to your favorable reply and to working with you at Transcept. 
 Sincerely, 
 Transcept Pharmaceuticals, Inc. 

 

	
	 /s/ Glenn A. Oclassen

	
	Glenn A. Oclassen
	President & Chief Executive Officer

 Agreed to and accepted: 
  

			
	Signature:	 	 /s/ John A. Kollins

		 	John A. Kollins
		
	Date:	 	5/31/12

 Enclosures: 
  

	 	•	 	 Duplicate Original Letter 

  

	 	•	 	 At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement 

 

	 	•	 	 Severance Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]